subject:(vaccine)

California State Polytechnic University – Pomona

1. Rubio, Jennifer. Efficacy Against Vaginal Herpes Virus Infection Using Adjuvants in a gD Tripeptide Liposomal Vaccine.

Degree: MS, Biological Sciences, 2018, California State Polytechnic University – Pomona

URL: http://hdl.handle.net/10211.3/199941

► Infections caused by Herpes Simplex 2 (HSV-2) manifest as painful, genital lesions with frequent recurrent episodes that cannot be cured by antiviral drug therapy, underscoring… (more)

▼ Infections caused by Herpes Simplex 2 (HSV-2) manifest as painful, genital lesions with frequent recurrent episodes that cannot be cured by antiviral drug therapy, underscoring the need for an effective vaccine. In our laboratory, we previously found that the HSV gD envelope protein (gD1-306-HD) in a liposomal vaccine could generate significant protection against intravaginal HSV-2 challenge in a murine model. The vaccines that our laboratory is developing focuses on three of the most immunogenic amino acid sequences within the gD protein (gD3pep). These studies aim to test the efficacy of gD1-306-HD, when incorporated into liposomes, or gD3pep-Cys with CMI liposomes or gD3pep-HD liposomal vaccines in combination with different adjuvants against an intravaginal HSV-2 challenge in Swiss Webster or BALB/c mice. The adjuvants bind with different receptors and include Monophosphoryl Lipid A (MPL) that binds with the TLR4 receptor, Lipidated or Non-Lipidated cyclic dinucleotide (CDN) that binds with the STING receptor, Lipidated Tucaresol (LT1) that binds with T cell receptors, 1V270 that binds with the TLR7 receptor and carbohydrates Trehalose Dibehenate (TDB) and Mifamurtide (Mif) which bind to C-type lectin receptor or NOD-like receptor, respectively. Liposomal vaccines were administered 3X subcutaneously to all mice on d0, d28, and d56. Negative controls were liposomes with no gD3pep or just phosphate buffered saline (PBS). Serum was collected from all groups on d59 and d60 to assess Neutralizing Antibody Titers and to perform ELISA anti-gD3pep IgG Isotyping. Splenocytes were also collected on d59 and d60 and used to investigate cytokine production via Luminex and ELISPOT assays. Mice were treated subcutaneously with Depo-Provera on d63 and d69. Treated mice were challenged intravaginally with 10X LD50 HSV-2 on d70 and monitored for morbidity 2X/day for 28 days. Vaginal swabs were collected on d72 to assess the viral burdens using a Plaque Forming Unit assay. All adjuvants, when incorporated into gD1-306-HD liposomes, or gD3pep-Cys CMI liposomes or gD3pep-HD liposomes generated significant protection against an HSV-2 intravaginal challenge based on prolonged survival and decreased viral burden. gD3pep-Cys liposomes with adjuvants 1V270, NLipCDN, LT1, MPL provided protection via stimulation and production of both Th1 and Th2 cytokines. Based on IgG isotyping ratios, gD3pep-Cys liposomes with the carbohydrates or PEP1 liposomes favored a protective Th2 response whereas PEP2 and PEP3 liposomes favored non-protectiveTh1 responses. Notably, gD3pep-Cys in CMI liposomes without adjuvant stimulated a protective immune response and suggested there is no advantage in using an adjuvant since gD3pep-Cys CMI liposomes without an adjuvant had consistently equal protection. We hypothesize that the CMI liposomes have some immunostimulatory properties and when combined with a multimeric display of the gD3pep antigen on the liposome surface, the liposomes are readily taken up by the antigen presenting cells. These observations… Advisors/Committee Members: Buckley, Nancy (committee member).

Subjects/Keywords: vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Rubio, J. (2018). Efficacy Against Vaginal Herpes Virus Infection Using Adjuvants in a gD Tripeptide Liposomal Vaccine. (Masters Thesis). California State Polytechnic University – Pomona. Retrieved from http://hdl.handle.net/10211.3/199941

Chicago Manual of Style (16^th Edition):

Rubio, Jennifer. “Efficacy Against Vaginal Herpes Virus Infection Using Adjuvants in a gD Tripeptide Liposomal Vaccine.” 2018. Masters Thesis, California State Polytechnic University – Pomona. Accessed June 24, 2019. http://hdl.handle.net/10211.3/199941.

MLA Handbook (7^th Edition):

Rubio, Jennifer. “Efficacy Against Vaginal Herpes Virus Infection Using Adjuvants in a gD Tripeptide Liposomal Vaccine.” 2018. Web. 24 Jun 2019.

Vancouver:

Rubio J. Efficacy Against Vaginal Herpes Virus Infection Using Adjuvants in a gD Tripeptide Liposomal Vaccine. [Internet] [Masters thesis]. California State Polytechnic University – Pomona; 2018. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/10211.3/199941.

Council of Science Editors:

Rubio J. Efficacy Against Vaginal Herpes Virus Infection Using Adjuvants in a gD Tripeptide Liposomal Vaccine. [Masters Thesis]. California State Polytechnic University – Pomona; 2018. Available from: http://hdl.handle.net/10211.3/199941

Université de Neuchâtel

2. Wyss, Jean-Christophe. Identification et caractérisation de protéines antigéniques de 'Borrelia burgdorferi' sensu lato.

Degree: 2012, Université de Neuchâtel

URL: http://doc.rero.ch/record/32347

► Borrelia afzelii, B. garinii, et B. burgdorferi sont trois des cinq espèces de Borrelia définitivement reconnues comme responsables de la borréliose de Lyme en Europe.… (more)

▼ Borrelia afzelii, B. garinii, et B. burgdorferi sont trois des cinq espèces de Borrelia définitivement reconnues comme responsables de la borréliose de Lyme en Europe. Cette maladie infectieuse est transmise par les tiques et se caractérise par des symptômes multiples en plusieurs étapes touchant le derme, les articulations, le système neurologique et cardiaque. Le but de cette étude est de révéler de nouvelles protéines antigéniques spécifiques de B. burgdorferi sensu lato et de les caractériser. L’'intérêt serait d’améliorer la détermination sérologique, la PCR de routine, et le diagnostic médical (symptômes / antigènes particuliers). Dans cette étude, deux approches globales ont été utilisées pour étudier les protéines antigéniques d'intérêts: une démarche protéomique et une démarche génomique. La partie protéomique consiste à étudier l’immunoprotéome de chaque espèce pathogène. Les fractions antigéniques des lysats protéiques totaux de B. burgdorferi sensu stricto VS215, B.garinii VS102 et B. afzelii VS461 ont été préparées en utilisant différentes colonnes d’immuno-affinités ayant une réactivité sérologique spécifique. Les protéines ont ensuite été séparées par électrophorèse bidimensionnelle pour obtenir des cartes de références spécifiques à chacune des espèces. 4 spots spécifiques ont été observés pour B. afzelii et 2 pour B. burgdorferi. La partie génomique consiste à étudier le protéome prédit de chaque espèce. Des algorithmes bioinformatiques ont été utilisés et une méthode a été décrite pour sélectionner les protéines potentiellement sécrétées par B. afzelii, B. burgdorferi et B.garinii (méthode rapide, facile et librement disponible à partir d’internet). Cette sélection a mis en évidence 3 candidats pour B. afzelii, 7 pour B. burgdorferi et 2 pour B.garinii. Ces deux approches donnent une vue de l’ensemble des antigènes de B. burgdorferi s.l. Finalement un exemple d’identification et de caractérisation de candidat a été faite. L'objectif de cette étude était d'identifier une protéine de 12 kDa de B. garinii réagissant avec l’anticorps monoclonal D6. La protéine a été extraite et soumise à une analyse de séquence LC-MS/MS. Cette analyse a révélé trois séquences polypeptidiques analogues à BB0477 (30S ribosomique S10), à BB0061 (thiorédoxine A), et à BB0390 (50 S ribosomique L7/L12). Les analyses génétiques ont été réalisées et deux polypeptides de la thiorédoxine A et un de la protéine ribosomique 50S ont ainsi été identifiés comme des épitoques potentiels. L’expression dans le vecteur PQR9 de E. coli suivie d’immunoblots a permit de montrer que les résidus 7-12 de la thiorédoxine A. sont reconnu par le D6. Cela a été confirmé par des expériences de compétition avec un peptide synthétique. Advisors/Committee Members: Oliver (Dir.), Bruno (Codir.).

Subjects/Keywords: Vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Wyss, J. (2012). Identification et caractérisation de protéines antigéniques de 'Borrelia burgdorferi' sensu lato. (Thesis). Université de Neuchâtel. Retrieved from http://doc.rero.ch/record/32347

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Wyss, Jean-Christophe. “Identification et caractérisation de protéines antigéniques de 'Borrelia burgdorferi' sensu lato.” 2012. Thesis, Université de Neuchâtel. Accessed June 24, 2019. http://doc.rero.ch/record/32347.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Wyss, Jean-Christophe. “Identification et caractérisation de protéines antigéniques de 'Borrelia burgdorferi' sensu lato.” 2012. Web. 24 Jun 2019.

Vancouver:

Wyss J. Identification et caractérisation de protéines antigéniques de 'Borrelia burgdorferi' sensu lato. [Internet] [Thesis]. Université de Neuchâtel; 2012. [cited 2019 Jun 24]. Available from: http://doc.rero.ch/record/32347.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Wyss J. Identification et caractérisation de protéines antigéniques de 'Borrelia burgdorferi' sensu lato. [Thesis]. Université de Neuchâtel; 2012. Available from: http://doc.rero.ch/record/32347

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

3. Jiz, Mario Antonio II L. Vaccine Development in Schistosomiasis japonica: Paramyosin As a Leading Candidate.

Degree: PhD, Division of Biology and Medicine. Pathobiology, 2009, Brown University

URL: https://repository.library.brown.edu/studio/item/bdr:175/

► Schistosomiasis is a chronic debilitating disease caused by helminths of the genus Schistosoma, and currently affecting millions in the developing world. Treatment with Praziquantel has… (more)

▼ Schistosomiasis is a chronic debilitating disease caused by helminths of the genus Schistosoma, and currently affecting millions in the developing world. Treatment with Praziquantel has reduced severe morbidities, however reinfection is common and subtle morbidities persist. Alternative control strategies such as vaccine-linked chemotherapy show great promise and warrant further development. This thesis describes vaccine development in schistosomiasis japonica, in conjunction with our recently concluded treatment-reinfection study of a Schistosoma japonicum-infected cohort in Leyte, Philippines (N=553). The promising vaccine candidate paramyosin remains under-evaluated due to challenges in large-scale recombinant production, and we address this need with a robust process to express and purify S. japonicum paramyosin (rSj97). Pilot scale production yielded 22.4 mg of >95% pure rSj97, with functional binding and structural properties similar to native paramyosin. Sera collected from the cohort one month post-treatment were analyzed for isotype-specific (IgA, IgE, IgG1, IgG4, total IgG) antibody responses to a panel of schistosome antigens (SWAP, rSj97, rSj67, rSj22) using a multiplexed bead-based assay. Repeated measures regression analysis with reinfection data up to 12 months post-treatment showed that IgE responses to rSj97 solely predicted resistance to reinfection (p=0.018), while IgG4 responses to all antigens associated with susceptibility, after adjusting for potential confounders. In combined IgE and IgG4 analysis to rSj97, individuals with only IgE responses had a 77% lower intensity of reinfection at 12 months post-treatment (p=0.016) compared to individuals with IgG4 but not IgE. Immunoscreening of an S. japonicum expression library for clones differentially recognized by the resistant but not susceptible subpopulation identified a novel vaccine candidate, Sj6-8. Sj6-8 was expressed in E. coli, and a similar repeated measures analysis demonstrated that IgE responses to rSj6-8 was marginally associated with resistance (p=0.065), predicting a 63% lower intensity of reinfection at 12 months post-treatment. Overall, this thesis further supports paramyosin as a leading vaccine candidate for schistosomiasis japonica, and our development of a pilot scale production process for rSj97 paves the way for further pre-clinical and eventual clinical testing of this promising vaccine candidate. Advisors/Committee Members: Kurtis, Jonathan (director), Knopf, Paul (reader), Friedman, Jennifer (reader), McGarvey, Stephen (reader), Reichner, Jonathan (reader).

Subjects/Keywords: vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Jiz, M. A. I. L. (2009). Vaccine Development in Schistosomiasis japonica: Paramyosin As a Leading Candidate. (Doctoral Dissertation). Brown University. Retrieved from https://repository.library.brown.edu/studio/item/bdr:175/

Chicago Manual of Style (16^th Edition):

Jiz, Mario Antonio II L. “Vaccine Development in Schistosomiasis japonica: Paramyosin As a Leading Candidate.” 2009. Doctoral Dissertation, Brown University. Accessed June 24, 2019. https://repository.library.brown.edu/studio/item/bdr:175/.

MLA Handbook (7^th Edition):

Jiz, Mario Antonio II L. “Vaccine Development in Schistosomiasis japonica: Paramyosin As a Leading Candidate.” 2009. Web. 24 Jun 2019.

Vancouver:

Jiz MAIL. Vaccine Development in Schistosomiasis japonica: Paramyosin As a Leading Candidate. [Internet] [Doctoral dissertation]. Brown University; 2009. [cited 2019 Jun 24]. Available from: https://repository.library.brown.edu/studio/item/bdr:175/.

Council of Science Editors:

Jiz MAIL. Vaccine Development in Schistosomiasis japonica: Paramyosin As a Leading Candidate. [Doctoral Dissertation]. Brown University; 2009. Available from: https://repository.library.brown.edu/studio/item/bdr:175/

4. 後藤, 正志. 癌免疫療法剤評価システムの開発 : Development of cancer immunotherapy medicine evaluation system; ガンメンエキリョウホウザイヒョウカシステムノカイハツ.

Degree: Nara Institute of Science and Technology / 奈良先端科学技術大学院大学

URL: http://hdl.handle.net/10061/4142

Subjects/Keywords: vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

後藤, �. (n.d.). 癌免疫療法剤評価システムの開発 : Development of cancer immunotherapy medicine evaluation system; ガンメンエキリョウホウザイヒョウカシステムノカイハツ. (Thesis). Nara Institute of Science and Technology / 奈良先端科学技術大学院大学. Retrieved from http://hdl.handle.net/10061/4142

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

後藤, 正志. “癌免疫療法剤評価システムの開発 : Development of cancer immunotherapy medicine evaluation system; ガンメンエキリョウホウザイヒョウカシステムノカイハツ.” Thesis, Nara Institute of Science and Technology / 奈良先端科学技術大学院大学. Accessed June 24, 2019. http://hdl.handle.net/10061/4142.

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

後藤, 正志. “癌免疫療法剤評価システムの開発 : Development of cancer immunotherapy medicine evaluation system; ガンメンエキリョウホウザイヒョウカシステムノカイハツ.” Web. 24 Jun 2019.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

後藤 �. 癌免疫療法剤評価システムの開発 : Development of cancer immunotherapy medicine evaluation system; ガンメンエキリョウホウザイヒョウカシステムノカイハツ. [Internet] [Thesis]. Nara Institute of Science and Technology / 奈良先端科学技術大学院大学; [cited 2019 Jun 24]. Available from: http://hdl.handle.net/10061/4142.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

Council of Science Editors:

後藤 �. 癌免疫療法剤評価システムの開発 : Development of cancer immunotherapy medicine evaluation system; ガンメンエキリョウホウザイヒョウカシステムノカイハツ. [Thesis]. Nara Institute of Science and Technology / 奈良先端科学技術大学院大学; Available from: http://hdl.handle.net/10061/4142

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

University of Hong Kong

5. Fan, Hiu-yan. Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review.

Degree: MPH, 2014, University of Hong Kong

URL: Fan, H. [樊曉欣]. (2014). Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320300 ; http://dx.doi.org/10.5353/th_b5320300 ; http://hdl.handle.net/10722/206903

►

Background Pneumococcal disease, caused by Streptococcus pneumoniae (S. pneumoniae), leads to a great burden of morbidity and mortality globally, especially in developing countries. World Health… (more)

▼

Background Pneumococcal disease, caused by Streptococcus pneumoniae (S. pneumoniae), leads to a great burden of morbidity and mortality globally, especially in developing countries. World Health Organization (WHO) estimated that 476,000 out of 8.8 million global annual deaths in children under 5 years old in 2008 were due to pneumococcal infection. Currently there are 2 second generation pneumococcal conjugate vaccines (PCVs) targeted at children, the 10-valent pneumococcal conjugate vaccine (PCV-10) and 13-valent pneumococcal conjugate vaccine (PCV-13) available in the market for the prevention of pneumococcal disease. Nowadays, about half of the countries already included PCVs into their National Immunization Programme (NIP) and around one-fourth are planning the introduction. The objective of this systematic review is to evaluate the cost-effectiveness of PCV-10 and PCV-13 so that the results could inform policy decisions of including PCVs into the NIP. Methods A systematic review was conducted by searching from 2 databases (PubMed and Medline) for the economic evaluation studies of the PCV-10 and PCV-13. Information of the design and characteristics of studies, burden of pneumococcal disease assumption, and baseline vaccine efficacy assumptions were extracted and results were presented in incremental cost-effectiveness ratio (ICER). Results Eleven studies were included, with 4 studies done in Europe, 3 in South America, 2 in Africa, 1 in Asia and 1 across North America and Europe. The results varied greatly among studies, with 5 of them reporting PCV-10 to be more cost-effective and/or cost-saving, while 4 of them reporting PCV-13 to be more cost-effective and/or cost-saving, and 2 of them concluded in a different way: PCV-10 was more cost-effective and cost-saving, however PCV-13 would lead to higher life-years gained (LYG) and/or disability-adjusted life years (DALYs) averted. Conclusion Due to the uncertainties in the clinical and epidemiological parameters, the unavailability of the data of local disease burden, and the analytical choices about endpoints which could significantly affect the input data, the results of the studies reviewed were contrasting from each other. Therefore, there was not enough evidence to show whether PCV-10 or PCV-13 was more cost-effective to be included into the NIP of children. Further research should be done on the sensitive variables of the cost-effectiveness ratio, as well as the local serotype distribution and disease burden should also be taken into account when planning the inclusion of PCVs into the NIP.

published_or_final_version

Public Health

Master

Master of Public Health

Subjects/Keywords: Pneumococcal vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Fan, H. (2014). Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review. (Masters Thesis). University of Hong Kong. Retrieved from Fan, H. [樊曉欣]. (2014). Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320300 ; http://dx.doi.org/10.5353/th_b5320300 ; http://hdl.handle.net/10722/206903

Chicago Manual of Style (16^th Edition):

Fan, Hiu-yan. “Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review.” 2014. Masters Thesis, University of Hong Kong. Accessed June 24, 2019. Fan, H. [樊曉欣]. (2014). Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320300 ; http://dx.doi.org/10.5353/th_b5320300 ; http://hdl.handle.net/10722/206903.

MLA Handbook (7^th Edition):

Fan, Hiu-yan. “Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review.” 2014. Web. 24 Jun 2019.

Vancouver:

Fan H. Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review. [Internet] [Masters thesis]. University of Hong Kong; 2014. [cited 2019 Jun 24]. Available from: Fan, H. [樊曉欣]. (2014). Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320300 ; http://dx.doi.org/10.5353/th_b5320300 ; http://hdl.handle.net/10722/206903.

Council of Science Editors:

Fan H. Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review. [Masters Thesis]. University of Hong Kong; 2014. Available from: Fan, H. [樊曉欣]. (2014). Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320300 ; http://dx.doi.org/10.5353/th_b5320300 ; http://hdl.handle.net/10722/206903

University of Hong Kong

6. Leung, May-bo, Mabel. The cost effectiveness of varicella vaccination program : a systemic review.

Degree: MPH, 2014, University of Hong Kong

URL: Leung, M. M. [梁美寶]. (2014). The cost effectiveness of varicella vaccination program : a systemic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320441 ; http://dx.doi.org/10.5353/th_b5320441 ; http://hdl.handle.net/10722/206948

►

Background Chickenpox is a common infectious disease among children. Ever since a live attenuated vaccine was developed in 1970s, different countries have adopted different vaccination… (more)

Subjects/Keywords: Chickenpox vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Leung, May-bo, M. (2014). The cost effectiveness of varicella vaccination program : a systemic review. (Masters Thesis). University of Hong Kong. Retrieved from Leung, M. M. [梁美寶]. (2014). The cost effectiveness of varicella vaccination program : a systemic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320441 ; http://dx.doi.org/10.5353/th_b5320441 ; http://hdl.handle.net/10722/206948

Chicago Manual of Style (16^th Edition):

Leung, May-bo, Mabel. “The cost effectiveness of varicella vaccination program : a systemic review.” 2014. Masters Thesis, University of Hong Kong. Accessed June 24, 2019. Leung, M. M. [梁美寶]. (2014). The cost effectiveness of varicella vaccination program : a systemic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320441 ; http://dx.doi.org/10.5353/th_b5320441 ; http://hdl.handle.net/10722/206948.

MLA Handbook (7^th Edition):

Leung, May-bo, Mabel. “The cost effectiveness of varicella vaccination program : a systemic review.” 2014. Web. 24 Jun 2019.

Vancouver:

Leung, May-bo M. The cost effectiveness of varicella vaccination program : a systemic review. [Internet] [Masters thesis]. University of Hong Kong; 2014. [cited 2019 Jun 24]. Available from: Leung, M. M. [梁美寶]. (2014). The cost effectiveness of varicella vaccination program : a systemic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320441 ; http://dx.doi.org/10.5353/th_b5320441 ; http://hdl.handle.net/10722/206948.

Council of Science Editors:

Leung, May-bo M. The cost effectiveness of varicella vaccination program : a systemic review. [Masters Thesis]. University of Hong Kong; 2014. Available from: Leung, M. M. [梁美寶]. (2014). The cost effectiveness of varicella vaccination program : a systemic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320441 ; http://dx.doi.org/10.5353/th_b5320441 ; http://hdl.handle.net/10722/206948

University of Hong Kong

7. 王筠婷; Wong, Kwan-ting. The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review.

Degree: MPH, 2014, University of Hong Kong

URL: Wong, K. [王筠婷]. (2014). The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320733 ; http://dx.doi.org/10.5353/th_b5320733 ; http://hdl.handle.net/10722/206978

►

BACKGROUND: Despite the current recommendation by the Centre for Health Protection (CHP)of Hong Kong for adults aged 65 years or above to receive 23-valent pneumococcal… (more)

▼

BACKGROUND: Despite the current recommendation by the Centre for Health Protection (CHP)of Hong Kong for adults aged 65 years or above to receive 23-valent pneumococcal polysaccharide vaccine (PPV23), pneumococcal disease(PD) has become the second leading causes of death in Hong Kong. A relatively new pneumococcal vaccine –13-valent pneumococcal conjugate vaccine (PCV13) was approved by the US Food and Drug Administration (FDA) in December 2011 and the European Medicines Agency (EMA) in July 2013 for the prevention of invasive disease caused by S. pneumoniae for older adults aged 50 years or above. It was shown to overcome some of the limitations of PPV23and potentially confer benefits to older adults in the prevention of PD. OBJECTIVES: To systematically review available literatures to examine whether PCV13 is superior to PPV23 or no vaccination in terms of the cost-effectiveness in the prevention of PD in older adults aged 50 years or above. METHODS: Two databases, PubMed and ISI Web of Science, were used to search for published journals. The year range of search in these databases was confined to10 years. RESULTS: A total of 318studies were identified initially and 10studies were included in this systematic review. Studies were conducted in the US, Colombia and European Union (EU) countries e.g. Italy, Germany, Netherlands and Spain. Different perspectives including societal, payer and health system were considered. The use of PCV13 was compared to either PPV23 or no vaccination in older adults aged 50 years or above. The coverage of PCV13 ranged from 42.4% to 70%, conferring an efficacy between 58% and 93.9%. The cost-effectiveness of PCV13 was expressed through the number of avoided cases/deaths for PD including invasive pneumococcal disease(IPD), inpatient and outpatient community-acquired pneumonia (CAP) as well as the incremental cost-effectiveness ratios (ICERs),either in cost per quality-adjusted life-year (QALY) gained or cost per life-year gained (LYG).Overall, PCV13 is shown to avoid more pneumococcal cases compared to PPV23 or no vaccination and is cost-effective in older adults aged 50 years of above. CONCLUSION: PCV13 is considered to be more cost-effective in older adults compared to PPV23 or no vaccination based on the current systematic review. Randomized controlled trials and cost-effectiveness evaluations are suggested to be conducted in Hong Kong and Asia-specific regions in order to obtain clinical and economic data of PCV13 in the Asian population. Policy-makers should also consider the effects of serotype replacement on the change in serotype distribution in local setting from time to time so that vaccines with appropriate serotype formulations could be researched.

published_or_final_version

Public Health

Master

Master of Public Health

Subjects/Keywords: Pneumococcal vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

王筠婷; Wong, K. (2014). The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review. (Masters Thesis). University of Hong Kong. Retrieved from Wong, K. [王筠婷]. (2014). The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320733 ; http://dx.doi.org/10.5353/th_b5320733 ; http://hdl.handle.net/10722/206978

Chicago Manual of Style (16^th Edition):

王筠婷; Wong, Kwan-ting. “The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review.” 2014. Masters Thesis, University of Hong Kong. Accessed June 24, 2019. Wong, K. [王筠婷]. (2014). The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320733 ; http://dx.doi.org/10.5353/th_b5320733 ; http://hdl.handle.net/10722/206978.

MLA Handbook (7^th Edition):

王筠婷; Wong, Kwan-ting. “The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review.” 2014. Web. 24 Jun 2019.

Vancouver:

王筠婷; Wong K. The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review. [Internet] [Masters thesis]. University of Hong Kong; 2014. [cited 2019 Jun 24]. Available from: Wong, K. [王筠婷]. (2014). The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320733 ; http://dx.doi.org/10.5353/th_b5320733 ; http://hdl.handle.net/10722/206978.

Council of Science Editors:

王筠婷; Wong K. The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review. [Masters Thesis]. University of Hong Kong; 2014. Available from: Wong, K. [王筠婷]. (2014). The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b5320733 ; http://dx.doi.org/10.5353/th_b5320733 ; http://hdl.handle.net/10722/206978

Baylor University

8. [No author]. Plant-produced, trans-encapsidated, replicative viral nanoparticles as a vaccine platform.

Degree: 2016, Baylor University

URL: http://hdl.handle.net/2104/9799

► Replicative virus-based vaccines provide potential solutions to avoid the natural deficits of traditional single-protein subunit vaccines. Unlike subunit vaccines, the infectious nature of viral particles… (more)

▼ Replicative virus-based vaccines provide potential solutions to avoid the natural deficits of traditional single-protein subunit vaccines. Unlike subunit vaccines, the infectious nature of viral particles can stimulate the innate immune response, which allows enhanced and elongated stimulation of antibody and T cell adaptive immunity. When these replicative vaccines are engineered to express antigen genes naturally in the patient's cells, cell mediated immunity is stimulated via the class I antigen presentation pathway, followed by a robust CD8+ T cell activation and interferon production. In this study, I aim to develop a safe, effective and cost-efficient transencapsidated replicative vaccine platform by encapsidating within strongly immunogenic tobacco mosaic virus (TMV) nanoparticles the self-replicative RNA of Flock House virus (FHV), an insect virus that also replicates in human and plant cells. By inserting the unique packaging signal of TMV into FHV RNA, the capsid of TMV assembles around the heterologous RNA, when TMV coat protein and FHV RNA are expressed in the same cell. First, the replication of different viral delivery vectors in both mammalian cells and plant cells was investigated and their cellular co-infection was demonstrated. The resulting successfully packaged chimeric nanoparticle improved antibody production over the standards after vaccination in mice. Next I detailed the specifics and techniques required to produce and purify these nanoparticle vaccines in planta via agroinoculation. To further explore the possibility of increasing the yield of plant-produced nanoparticle vaccines, an optimized spray-on inoculation method was developed using a low-toxicity surfactant to aid agro-inoculation. Unexpectedly, this also decreased contaminating plant pathogenesis-related proteins. A continuing study is also discussed on trans-locating FHV replication to endoplasmic reticulum, which suggests potential to further increase plant yield of nanoparticle vaccines as well. Advisors/Committee Members: Kearney, Christopher Michel, 1958- (advisor).

Subjects/Keywords: Virus. Vaccine.

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

author], [. (2016). Plant-produced, trans-encapsidated, replicative viral nanoparticles as a vaccine platform. (Thesis). Baylor University. Retrieved from http://hdl.handle.net/2104/9799

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

author], [No. “Plant-produced, trans-encapsidated, replicative viral nanoparticles as a vaccine platform. ” 2016. Thesis, Baylor University. Accessed June 24, 2019. http://hdl.handle.net/2104/9799.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

author], [No. “Plant-produced, trans-encapsidated, replicative viral nanoparticles as a vaccine platform. ” 2016. Web. 24 Jun 2019.

Vancouver:

author] [. Plant-produced, trans-encapsidated, replicative viral nanoparticles as a vaccine platform. [Internet] [Thesis]. Baylor University; 2016. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/2104/9799.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

author] [. Plant-produced, trans-encapsidated, replicative viral nanoparticles as a vaccine platform. [Thesis]. Baylor University; 2016. Available from: http://hdl.handle.net/2104/9799

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Boston University

9. Alonso, Adrian Miguel. Development of a multiple antigen presenting system (MAPS) vaccine for Group B Streptoccocus.

Degree: MS, Medical Sciences, 2018, Boston University

URL: http://hdl.handle.net/2144/30870

► BACKGROUND: Group B Streptococcus (GBS) is a Gram-positive bacterium that is a common cause of infection in neonates and is the predominant pathogen causing meningitis… (more)

▼ BACKGROUND: Group B Streptococcus (GBS) is a Gram-positive bacterium that is a common cause of infection in neonates and is the predominant pathogen causing meningitis in infants. Different vaccine formulations have been evaluated in preclinical and/or clinical settings, such as polysaccharide-based vaccines, protein-based, polysaccharide-protein conjugate vaccines, and most recently a Multiple Antigen Presenting System (MAPS) vaccine. MAPS is a vaccine that is being developed in the Malley laboratory at Boston Children’s Hospital that consists of GBS polysaccharides and proteins that are combined using affinity interactions. The overall aim of this thesis is to contribute towards the development of an effective MAPS vaccine by identifying high capsule-producing GBS isolates, optimizing conditions for polysaccharide purifications, characterizing the immune response to carrier protein derivatives, and creating MAPS complexes with GBS-specific protein carriers. METHODS: The serotypes of 61 GBS clinical isolates were identified via multiplex PCR. To determine high producing strains, the supernatant polysaccharide concentrations (SPC) for type Ia and III were measured by type 14 pneumococcal and GBS Ia ELISAs, respectively. In addition, type III isolates were grown in different conditions (shaking vs. static, Todd Hewitt Broth vs. Todd Hewitt Broth + 0.5% yeast extracts). For carrier protein production, genetically conserved alpC and rib were ligated onto a pet21b C terminally tagged rhizavidin (protein made by Rhizobium etli that has a very high affinity for biotin) vector. AlpC was purified and used to immunize rabbits. To determine whether the location of the terminal rhizavidin tag affected the immunogenicity of the proteins, we compared the serum titers of C- and N-terminally tagged proteins by ELISA. Additionally, AlpC was conjugated to purified pneumococcal type I polysaccharide for the creation of MAPS complexes. RESULTS: We serotyped 61 clinical GBS isolates, of which 18 were type Ia and 33 were type III. The type Ia isolate 21 and type III isolate 25 produced the most polysaccharide relative to the other isolates. The majority of the isolates for type III produced more capsule under shaking conditions and when grown in THY (Todd Hewitt Broth +0.5% yeast extracts). AlpC and rib were successfully cloned into pet21b CRhiz plasmid and purified. To determine if the position of the rhizavadin tag affected immunogenicity, AlpC-C terminus was sent for immunization onto rabbits. This protein generated similar antibody titers than a N-terminally tagged AlpC. DISCUSSION: The majority of isolates identified from patients were type Ia and III which corresponds to published data stating that Ia and III are amongst the most common serotypes associated with early onset disease. Production of capsule was greatest in isolate 21 for the Ias and isolate 25 for the III, which may be due to enhanced expression of the cps operon. The data for serum titers from AlpC revealed no major difference between titers generated by the… Advisors/Committee Members: Franzblau, Carl (advisor), Malley, Richard (advisor).

Subjects/Keywords: Microbiology; Vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Alonso, A. M. (2018). Development of a multiple antigen presenting system (MAPS) vaccine for Group B Streptoccocus. (Masters Thesis). Boston University. Retrieved from http://hdl.handle.net/2144/30870

Chicago Manual of Style (16^th Edition):

Alonso, Adrian Miguel. “Development of a multiple antigen presenting system (MAPS) vaccine for Group B Streptoccocus.” 2018. Masters Thesis, Boston University. Accessed June 24, 2019. http://hdl.handle.net/2144/30870.

MLA Handbook (7^th Edition):

Alonso, Adrian Miguel. “Development of a multiple antigen presenting system (MAPS) vaccine for Group B Streptoccocus.” 2018. Web. 24 Jun 2019.

Vancouver:

Alonso AM. Development of a multiple antigen presenting system (MAPS) vaccine for Group B Streptoccocus. [Internet] [Masters thesis]. Boston University; 2018. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/2144/30870.

Council of Science Editors:

Alonso AM. Development of a multiple antigen presenting system (MAPS) vaccine for Group B Streptoccocus. [Masters Thesis]. Boston University; 2018. Available from: http://hdl.handle.net/2144/30870

10. Delaney, Kristen. A Flagellin-Poxvirus Antigen Vaccine: Strengths and Limitations.

Degree: 2009, Wake Forest University

URL: http://hdl.handle.net/10339/14912

► Bacterial flagellin is a potent adjuvant that enhances adaptive immune responses to a variety of antigens. The vaccinia virus antigens L1R and B5R are highly… (more)

▼ Bacterial flagellin is a potent adjuvant that enhances adaptive immune responses to a variety of antigens. The vaccinia virus antigens L1R and B5R are highly immunogenic in the context of the parent virus, but recombinant forms of the proteins are only weakly immunogenic. Therefore, we evaluated the response to these antigens when flagellin was used as an adjuvant. Although flagellin promoted a robust antigen-specific humoral response to poxvirus antigens delivered intranasally (i.n.) or intramuscularly (i.m.), intramuscular immunization resulted in significantly high titers of anti-L1R and B5R IgG. Flagellin/poxvirus antigen fusion proteins were more potent than flagellin and L1R and B5R as separate proteins as inducers of a humoral response against the poxvirus antigens. At least three immunizations with flagellin/poxvirus fusion proteins were required to confer protection in mice against challenge with vaccinia virus. Although mice were protected and exhibited only limited signs of disease, they still exhibited significant, but reversible weight loss. When immune mice were depleted of complement using cobra venom factor, 50% of the mice succumbed to vaccinia virus infection. These results demonstrate that flagellin-poxvirus antigen fusion proteins are effective in eliciting protective immunity against vaccinia virus that is dependent, in part, on complement. We evaluated the efficacy of additional flagellin-poxvirus antigen constructs to promote protective immunity and found that antigens can lose their immunogenicity when inserted into certain regions of flagellin. The loss of immunogenicity is dependent on the individual antigen, and was not the same for all antigens tested. When administering more than one immunogenic fusion protein antigen-specific titers decrease slightly, and the addition of excess flagellin will further decrease titers suggesting that there is a limit to the number of fusion proteins that can be administered in a single vaccine.

Subjects/Keywords: vaccine

…flagellin-pox antigen fusion vaccine 48 13 Plasma from immunized mice is capable of… …ABSTRACT Delaney, Kristen N. A FLAGELLIN-POXVIRUS ANTIGEN VACCINE: STRENGTHS AND LIMITATIONS… …can be administered in a single vaccine. x INTRODUCTION Variola Virus Pathogenesis and… …not permitted, vaccinia virus is used as a model agent in poxvirus vaccine studies… …remains infectious. It has been shown that acellular vaccine strategies that target both…

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Delaney, K. (2009). A Flagellin-Poxvirus Antigen Vaccine: Strengths and Limitations. (Thesis). Wake Forest University. Retrieved from http://hdl.handle.net/10339/14912

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Delaney, Kristen. “A Flagellin-Poxvirus Antigen Vaccine: Strengths and Limitations.” 2009. Thesis, Wake Forest University. Accessed June 24, 2019. http://hdl.handle.net/10339/14912.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Delaney, Kristen. “A Flagellin-Poxvirus Antigen Vaccine: Strengths and Limitations.” 2009. Web. 24 Jun 2019.

Vancouver:

Delaney K. A Flagellin-Poxvirus Antigen Vaccine: Strengths and Limitations. [Internet] [Thesis]. Wake Forest University; 2009. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/10339/14912.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Delaney K. A Flagellin-Poxvirus Antigen Vaccine: Strengths and Limitations. [Thesis]. Wake Forest University; 2009. Available from: http://hdl.handle.net/10339/14912

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

11. Smedberg, Jason. Determining the Innate and Adaptive Immune Responses to Vesicular Stomatitis Virus Vaccine Vectors.

Degree: 2014, Wake Forest University

URL: http://hdl.handle.net/10339/39297

► Vesicular stomatitis virus (VSV) vaccine vectors have been engineered to express many different antigens. Studies in mice and nonhuman primates have demonstrated efficacy against several… (more)

Subjects/Keywords: Vaccine

…ABSTRACT Vesicular stomatitis virus (VSV) vaccine vectors have been engineered… …efficacy against several pathogens. A novel strategy to enhance VSV as an effective vaccine is to… …engineer vectors that induce innate immune mechanisms. We have generated an improved VSV vaccine… …prevents the virus from suppressing host responses and the addition of a vaccine adjuvant… …flagellin. VSV is currently in clinical trials as a recombinant vaccine vector against…

13 more images…

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Smedberg, J. (2014). Determining the Innate and Adaptive Immune Responses to Vesicular Stomatitis Virus Vaccine Vectors. (Thesis). Wake Forest University. Retrieved from http://hdl.handle.net/10339/39297

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Smedberg, Jason. “Determining the Innate and Adaptive Immune Responses to Vesicular Stomatitis Virus Vaccine Vectors.” 2014. Thesis, Wake Forest University. Accessed June 24, 2019. http://hdl.handle.net/10339/39297.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Smedberg, Jason. “Determining the Innate and Adaptive Immune Responses to Vesicular Stomatitis Virus Vaccine Vectors.” 2014. Web. 24 Jun 2019.

Vancouver:

Smedberg J. Determining the Innate and Adaptive Immune Responses to Vesicular Stomatitis Virus Vaccine Vectors. [Internet] [Thesis]. Wake Forest University; 2014. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/10339/39297.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Smedberg J. Determining the Innate and Adaptive Immune Responses to Vesicular Stomatitis Virus Vaccine Vectors. [Thesis]. Wake Forest University; 2014. Available from: http://hdl.handle.net/10339/39297

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Minnesota

12. Crabtree, Juliet. The Function of PTPN22 and the Autoimmune Risk Variant LypW in Immune Responses to Vaccination.

Degree: PhD, Microbiology, Immunology and Cancer Biology, 2016, University of Minnesota

URL: http://hdl.handle.net/11299/182251

► High-affinity antibody production, T cell activation, and Interferon upregulation all contribute to protective immunity that occurs in humans following influenza immunization. Hematopoietic cell-specific PTPN22 encodes… (more)

Subjects/Keywords: PTPN22; Vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Crabtree, J. (2016). The Function of PTPN22 and the Autoimmune Risk Variant LypW in Immune Responses to Vaccination. (Doctoral Dissertation). University of Minnesota. Retrieved from http://hdl.handle.net/11299/182251

Chicago Manual of Style (16^th Edition):

Crabtree, Juliet. “The Function of PTPN22 and the Autoimmune Risk Variant LypW in Immune Responses to Vaccination.” 2016. Doctoral Dissertation, University of Minnesota. Accessed June 24, 2019. http://hdl.handle.net/11299/182251.

MLA Handbook (7^th Edition):

Crabtree, Juliet. “The Function of PTPN22 and the Autoimmune Risk Variant LypW in Immune Responses to Vaccination.” 2016. Web. 24 Jun 2019.

Vancouver:

Crabtree J. The Function of PTPN22 and the Autoimmune Risk Variant LypW in Immune Responses to Vaccination. [Internet] [Doctoral dissertation]. University of Minnesota; 2016. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/11299/182251.

Council of Science Editors:

Crabtree J. The Function of PTPN22 and the Autoimmune Risk Variant LypW in Immune Responses to Vaccination. [Doctoral Dissertation]. University of Minnesota; 2016. Available from: http://hdl.handle.net/11299/182251

13. Bello, Alexander Juanito Arquillano. Linking the tropism and transduction efficiency of porcine-derived adeno-associated viruses to their transgene-mediated protective efficacy.

Degree: Medical Microbiology, 2014, University of Manitoba

URL: http://hdl.handle.net/1993/23945

► Adeno-associated virus (AAV) is a small, non-pathogenic virus, exploited as a vector for gene therapy applications, with many successful clinical trials. However, these vectors are… (more)

▼ Adeno-associated virus (AAV) is a small, non-pathogenic virus, exploited as a vector for gene therapy applications, with many successful clinical trials. However, these vectors are based on human and non-human primate AAVs, to which there exists pre-existing immunity in the general population. We hypothesized AAVs having low seroprevalence in the human population can be isolated from alternate sources and can be an alternative to those used in current clinical trials. We also hypothesized that the close homology between pig and human tissues suggests that AAVs isolated from pigs would be able to transduce human cells efficiently. Porcine-derived AAVs preferred specific tissue targets when injected in vivo in mice and successfully transduced cells derived from humans. Immune responses generated against the AAV capsid are also important for determining the safety profile of the vectors; there still exists the possibility of the host mounting adverse immune responses against transduced cells, as seen in some of clinical trials. Although the transduction efficiency of AAV gene transfer has been extensively studied in animal models, the host’s immune response towards the gene product is still poorly understood. This thesis addresses the issue by providing a link between protective efficacy against lethal challenge and tissue tropism. Here, AAVs carrying an immunogenic transgene were developed, with the goal to identify those that can protect against lethal challenge of avian flu or Ebola virus in mice, and those that had poor protective efficacy. It was observed that the protective efficacy afforded by an AAV was serotype specific. The protective efficacy and immune responses were compared to the biodistribution and cellular targets of each AAV. Overall, AAVs sharing broad tropism in biodistribution studies had a tendency to protect mice against lethal challenge than those AAVs not found systemically. As well, those AAVs eliciting protective efficacy against lethal challenge were able to transduce antigen-presenting cells including dendritic and B cells. The link between tissue tropism and host immune responses has been poorly understood and this thesis contributes to the AAV field by highlighting the significance of the cellular targets of AAV and this relationship to protective efficacy. Advisors/Committee Members: Kobinger, Gary (Medical Microbiology) (supervisor), Fowke, Keith (Medical Microbiology) Yao, Xiaojian (Medical Microbiology) Kung, Sam (Immunology) Simpson, Elizabeth (University of British Columbia) (examiningcommittee).

Subjects/Keywords: AAV; Vaccine

12 more images…

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Bello, A. J. A. (2014). Linking the tropism and transduction efficiency of porcine-derived adeno-associated viruses to their transgene-mediated protective efficacy. (Thesis). University of Manitoba. Retrieved from http://hdl.handle.net/1993/23945

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Bello, Alexander Juanito Arquillano. “Linking the tropism and transduction efficiency of porcine-derived adeno-associated viruses to their transgene-mediated protective efficacy.” 2014. Thesis, University of Manitoba. Accessed June 24, 2019. http://hdl.handle.net/1993/23945.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Bello, Alexander Juanito Arquillano. “Linking the tropism and transduction efficiency of porcine-derived adeno-associated viruses to their transgene-mediated protective efficacy.” 2014. Web. 24 Jun 2019.

Vancouver:

Bello AJA. Linking the tropism and transduction efficiency of porcine-derived adeno-associated viruses to their transgene-mediated protective efficacy. [Internet] [Thesis]. University of Manitoba; 2014. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/1993/23945.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Bello AJA. Linking the tropism and transduction efficiency of porcine-derived adeno-associated viruses to their transgene-mediated protective efficacy. [Thesis]. University of Manitoba; 2014. Available from: http://hdl.handle.net/1993/23945

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Georgia State University

14. Arana, Jorge E. Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal Conjugate Vaccine and 7-Valent Pneumococcal Conjugate Vaccine: Data from the Vaccine Advere Event Reporting System (Vaers).

Degree: MPH, Public Health, 2011, Georgia State University

URL: https://scholarworks.gsu.edu/iph_theses/159

► Comparison of Post-licensure safety surveillance of 13-Valent Pneumococcal Conjugate vaccine and 7-Valent Pneumococcal Conjugate vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS).… (more)

Subjects/Keywords: Pneumococcal vaccine; vaccine; adverse event; Public Health

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Arana, J. E. (2011). Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal Conjugate Vaccine and 7-Valent Pneumococcal Conjugate Vaccine: Data from the Vaccine Advere Event Reporting System (Vaers). (Thesis). Georgia State University. Retrieved from https://scholarworks.gsu.edu/iph_theses/159

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Arana, Jorge E. “Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal Conjugate Vaccine and 7-Valent Pneumococcal Conjugate Vaccine: Data from the Vaccine Advere Event Reporting System (Vaers).” 2011. Thesis, Georgia State University. Accessed June 24, 2019. https://scholarworks.gsu.edu/iph_theses/159.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Arana, Jorge E. “Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal Conjugate Vaccine and 7-Valent Pneumococcal Conjugate Vaccine: Data from the Vaccine Advere Event Reporting System (Vaers).” 2011. Web. 24 Jun 2019.

Vancouver:

Arana JE. Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal Conjugate Vaccine and 7-Valent Pneumococcal Conjugate Vaccine: Data from the Vaccine Advere Event Reporting System (Vaers). [Internet] [Thesis]. Georgia State University; 2011. [cited 2019 Jun 24]. Available from: https://scholarworks.gsu.edu/iph_theses/159.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Arana JE. Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal Conjugate Vaccine and 7-Valent Pneumococcal Conjugate Vaccine: Data from the Vaccine Advere Event Reporting System (Vaers). [Thesis]. Georgia State University; 2011. Available from: https://scholarworks.gsu.edu/iph_theses/159

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Saskatchewan

15. Lobanova, Liubov M. Development of novel vaccine candidates for measles.

Degree: 2010, University of Saskatchewan

URL: http://hdl.handle.net/10388/etd-01042011-135829

► Despite the availability of live attenuated measles virus vaccines, a large number of measles-associated deaths occur among infants in developing countries during the "window of… (more)

▼ Despite the availability of live attenuated measles virus vaccines, a large number of measles-associated deaths occur among infants in developing countries during the "window of susceptibility" (age 4-9 months). During this period declining maternal antibody titers are no longer protective against wild-type measles virus (MV) and impede successful immunization with the live attenuated vaccines. Therefore, the development of a safe vaccine that would induce protective immunity in the presence of maternally derived MV-specific antibodies in young infants and would close the "window of susceptibility" is desirable. Since adenoviruses have been shown as suitable vaccine candidates capable of eliciting potent protection against mucosal infectious diseases, the ability of an adenovirus-vectored anti-measles vaccine to elicit robust immune responses against MV was assessed in this study. Mice immunized intramuscularly or intranasally with a combination of human adenovirus serotype 5 (Ad5) recombinants expressing MV hemagglutinin (H) and fusion (F) glycoproteins developed MV-specific neutralizing antibody titers similar for both routes of immunization. However, intramuscular immunization of mice with Ad5 recombinants resulted in induction of a predominant T helper type (Th1) immune response, whereas intranasal immunization induced a balanced Th1/Th2 immune response. Furthermore, intranasal immunization resulted in increased titers of MV-specific immunoglobulin A (IgA) in lungs in comparison to intramuscularly immunized animals. The ability of the Ad5 recombinants to induce protective immune responses in cotton rats by different routes of administration was also evaluated. Cotton rats that received a single dose of the Ad5 recombinants intramuscularly or intranasally experienced a rise in MV-specific neutralizing antibody titers and reduction of the viral RNA load in the lung tissue after intranasal MV challenge. In addition, the largest reduction in viral replication was observed in the group of cotton rats inoculated with the Ad5 recombinants intranasally. Based on these observations, the Ad5-based vaccine appears to be a suitable candidate against measles. Furthermore, a capability of purified globular head domain of MV H protein produced in a human cell line to induce MV-specific immune responses in mice was tested. Subcutaneous immunization of mice with the recombinant protein alone resulted in both humoral and cell-mediated immunity, characterized by the production of MV-specific serum IgG and neutralizing antibodies, as well as interferon-gamma and interleukin 5 (IL-5) production by in vitro restimulated splenocytes. The former responses were further enhanced by formulation of the protein with aluminium hydroxide. However, very low numbers of INF-gamma secreting cells and low levels of IgG2a in the serum suggested a Th2 immune response. Novel adjuvants (Th1-directing), as well as MV F protein should be considered for the inclusion into the vaccine formulations to induce more balanced Th1/Th2 immune responses against… Advisors/Committee Members: Chelico, Linda.

Subjects/Keywords: measles; adenovirus; vaccine formulations; immune responses; vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Lobanova, L. M. (2010). Development of novel vaccine candidates for measles. (Thesis). University of Saskatchewan. Retrieved from http://hdl.handle.net/10388/etd-01042011-135829

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Lobanova, Liubov M. “Development of novel vaccine candidates for measles.” 2010. Thesis, University of Saskatchewan. Accessed June 24, 2019. http://hdl.handle.net/10388/etd-01042011-135829.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Lobanova, Liubov M. “Development of novel vaccine candidates for measles.” 2010. Web. 24 Jun 2019.

Vancouver:

Lobanova LM. Development of novel vaccine candidates for measles. [Internet] [Thesis]. University of Saskatchewan; 2010. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/10388/etd-01042011-135829.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Lobanova LM. Development of novel vaccine candidates for measles. [Thesis]. University of Saskatchewan; 2010. Available from: http://hdl.handle.net/10388/etd-01042011-135829

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Arizona

16. Rivera, Jocelyn Renee. Development and Evaluation of a Clinical Practice Guideline to Promote an Evidence-based Approach to Vaccine Hesitancy in Primary Care .

Degree: 2017, University of Arizona

URL: http://hdl.handle.net/10150/626638

► The purpose of this project is to develop a clinical practice guideline with recommendations for vaccination and vaccine hesitancy in the pediatric setting. Routine vaccinations… (more)

▼ The purpose of this project is to develop a clinical practice guideline with recommendations for vaccination and vaccine hesitancy in the pediatric setting. Routine vaccinations are given to children at recommended ages to decrease the incidence of, and prevent infectious disease. These vaccinations prevent diseases such as rotavirus, diphtheria, pertussis, tetanus, hepatitis B, haemophilus influenza type B, pneumococcal disease, polio, influenza, measles, mumps, rubella, varicella and hepatitis A. There are currently no guidelines that combine evidence-based interventions to increase vaccination rates, the recommended vaccine schedule, specific information on each vaccination, its side effects, and ingredients of each vaccination. By developing this guideline, it is hoped that pediatric providers will be able to effectively approach the caregivers of vaccine-aged children with evidence based information about vaccination, and be able to address specific concerns regarding vaccines. The available literature was formally evaluated using GRADEpro software. These results were put into the BRIDGE-Wiz (Building Recommendations in a Developer ’s Guideline Editor) software to create clear, concise, key action statements for the guideline. There were five recommendations that were created based on the literature review which include assessing parental concerns regarding vaccination at each visit, educating parents on vaccination, each vaccine, at each visit and when concerns arise, recommending vaccinations during each visit and when the opportunity arises, recommending pre-scheduling vaccination appointments, and implementing a reminder/recall system when vaccinations are due or past due. There were also informational tables created for provider reference that include important information regarding vaccines. The first table includes each vaccination, the disease it prevents, and the risk of the disease vs the risk of the vaccination. The second table includes the vaccine ingredients that commonly cause concern, and information to address those concerns. The guideline can be used in pediatric primary care to guide interventions to increase the uptake of vaccinations, and as a tool for providers to use while educating parents on specific vaccinations. The guideline was formally evaluated using the AGREE II tool by three experts in the field of pediatric primary care. All three of the reviewers stated that they would recommend the guideline for use in the pediatric setting. Advisors/Committee Members: Peek, Gloanna (advisor), Peek, Gloanna (committeemember), Bencs, Nicole (committeemember), Williams, Deborah (committeemember).

Subjects/Keywords: immunization; vaccination; vaccine education; vaccine hesitancy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Rivera, J. R. (2017). Development and Evaluation of a Clinical Practice Guideline to Promote an Evidence-based Approach to Vaccine Hesitancy in Primary Care . (Doctoral Dissertation). University of Arizona. Retrieved from http://hdl.handle.net/10150/626638

Chicago Manual of Style (16^th Edition):

Rivera, Jocelyn Renee. “Development and Evaluation of a Clinical Practice Guideline to Promote an Evidence-based Approach to Vaccine Hesitancy in Primary Care .” 2017. Doctoral Dissertation, University of Arizona. Accessed June 24, 2019. http://hdl.handle.net/10150/626638.

MLA Handbook (7^th Edition):

Rivera, Jocelyn Renee. “Development and Evaluation of a Clinical Practice Guideline to Promote an Evidence-based Approach to Vaccine Hesitancy in Primary Care .” 2017. Web. 24 Jun 2019.

Vancouver:

Rivera JR. Development and Evaluation of a Clinical Practice Guideline to Promote an Evidence-based Approach to Vaccine Hesitancy in Primary Care . [Internet] [Doctoral dissertation]. University of Arizona; 2017. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/10150/626638.

Council of Science Editors:

Rivera JR. Development and Evaluation of a Clinical Practice Guideline to Promote an Evidence-based Approach to Vaccine Hesitancy in Primary Care . [Doctoral Dissertation]. University of Arizona; 2017. Available from: http://hdl.handle.net/10150/626638

Texas A&M University

17. Carroll, Juliette E. Babesia microti Recombinant DNA Vaccine as a Model for Babesia bovis Prevention.

Degree: 2011, Texas A&M University

URL: http://hdl.handle.net/1969.1/ETD-TAMU-2009-12-7248

► Babesiosis is caused by a genus of tick-transmitted apicomplexan parasites with considerable economic, medical, and veterinary impact. Bovine babesiosis is an important impediment to livestock… (more)

Subjects/Keywords: Babesia spp. vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Carroll, J. E. (2011). Babesia microti Recombinant DNA Vaccine as a Model for Babesia bovis Prevention. (Thesis). Texas A&M University. Retrieved from http://hdl.handle.net/1969.1/ETD-TAMU-2009-12-7248

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Carroll, Juliette E. “Babesia microti Recombinant DNA Vaccine as a Model for Babesia bovis Prevention.” 2011. Thesis, Texas A&M University. Accessed June 24, 2019. http://hdl.handle.net/1969.1/ETD-TAMU-2009-12-7248.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Carroll, Juliette E. “Babesia microti Recombinant DNA Vaccine as a Model for Babesia bovis Prevention.” 2011. Web. 24 Jun 2019.

Vancouver:

Carroll JE. Babesia microti Recombinant DNA Vaccine as a Model for Babesia bovis Prevention. [Internet] [Thesis]. Texas A&M University; 2011. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/1969.1/ETD-TAMU-2009-12-7248.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Carroll JE. Babesia microti Recombinant DNA Vaccine as a Model for Babesia bovis Prevention. [Thesis]. Texas A&M University; 2011. Available from: http://hdl.handle.net/1969.1/ETD-TAMU-2009-12-7248

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

18. Deal, Cailin E. Conserved epitopes in Plasmodium falciparum and influenza A virus as targets for virus-vectored immunization.

Degree: 2014, Johns Hopkins University

URL: http://jhir.library.jhu.edu/handle/1774.2/37971

► The development of vaccines against infectious diseases has been highly successful. However, while effective vaccines have been licensed against many diseases such as smallpox, polio,… (more)

▼ The development of vaccines against infectious diseases has been highly successful. However, while effective vaccines have been licensed against many diseases such as smallpox, polio, measles, rubella, mumps, varicella, diphtheria, tetanus and pertussis, there are still a number of infectious diseases that continue to wreak havoc on public health. Many attempts have been made to create vaccines against intractable pathogens, such as HIV, malaria, and influenza A virus (IAV), but the construction of vaccines that induce broadly protective immunity against these diseases has proven difficult. This necessitates further research into conserved epitopes and new vaccine approaches. In this study, I investigate the role of a highly conserved epitope of influenza A virus, the M2 extracellular domain (M2e), in the viral life cycle; this region has become a major molecular target for universal IAV vaccines. Using in vitro transcomplementation assays with cell lines stably expressing M2e mutants, we determined that this region of the M2 protein is tolerable of mutations since directed alanine mutagenesis nor deletion of several amino acids attenuated IAV replication. This suggests that this portion of M2e is not required for function and that alternative reasons exist for the high conservation. In addition, the use of viral vectors for vaccines was investigated. Adenovirus (Ad) is a highly immunogenic viral vector. Recombinant Ads that display either the M2e or conserved HA2 alpha helix (HA2A) of IAV in hexon hypervariable regions were examined as potential universal influenza A vaccines. While these recombinant Ads were successfully created, they were not immunogenic in mice. Induction of effective immune responses by conventional vaccination methods is uncertain, especially for pathogens such as malaria and HIV. As an alternative to relying on an individuals’ immune system to mount a protective response, adeno-associated virus (AAV) was used to express previously characterized human broadly neutralizing monoclonal antibodies to the Plasmodium falciparum circumsporozoite protein (CSP) as a transgene. This ‘vectored immunoprophylaxis’ (VIP) approach allowed for rapid and high sustained expression of monoclonal antibodies to CSP that were capable of protecting mice from stringent sporozoite challenge, making this a viable approach for malaria prevention. Advisors/Committee Members: Guggino, William (advisor).

Subjects/Keywords: vaccine; virus-vectors

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Deal, C. E. (2014). Conserved epitopes in Plasmodium falciparum and influenza A virus as targets for virus-vectored immunization. (Thesis). Johns Hopkins University. Retrieved from http://jhir.library.jhu.edu/handle/1774.2/37971

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Deal, Cailin E. “Conserved epitopes in Plasmodium falciparum and influenza A virus as targets for virus-vectored immunization.” 2014. Thesis, Johns Hopkins University. Accessed June 24, 2019. http://jhir.library.jhu.edu/handle/1774.2/37971.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Deal, Cailin E. “Conserved epitopes in Plasmodium falciparum and influenza A virus as targets for virus-vectored immunization.” 2014. Web. 24 Jun 2019.

Vancouver:

Deal CE. Conserved epitopes in Plasmodium falciparum and influenza A virus as targets for virus-vectored immunization. [Internet] [Thesis]. Johns Hopkins University; 2014. [cited 2019 Jun 24]. Available from: http://jhir.library.jhu.edu/handle/1774.2/37971.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Deal CE. Conserved epitopes in Plasmodium falciparum and influenza A virus as targets for virus-vectored immunization. [Thesis]. Johns Hopkins University; 2014. Available from: http://jhir.library.jhu.edu/handle/1774.2/37971

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

19. MORAN, HANNAH. The immunmodulatory properties of chitin-derived polymers are dictated by their deacetylation patterns.

Degree: School of Biochemistry & Immunology. Discipline of Biochemistry, 2018, Trinity College Dublin

URL: http://hdl.handle.net/2262/82147

► The introduction of vaccines is regarded as one of the most successful medical interventions to date, due to their effectiveness at combating diseases that require… (more)

▼ The introduction of vaccines is regarded as one of the most successful medical interventions to date, due to their effectiveness at combating diseases that require the induction of a robust immune response. However there is a clear need for the development of new vaccines for diseases including HIV, TB and malaria and for cancer which require the induction of a potent cellular immune response. Advancements in the field of vaccine research have resulted in a move away from the use of whole organisms and towards the use of subunit vaccines which consist of highly purified antigens and thus offer a much more attractive safety profile. Adjuvants are immunostimulatory components that are included in subunit vaccine formulations to help to direct and amplify an appropriate adaptive immune response. The most commonly used adjuvant to date, alum, is incorporated into vaccine formulations that are aimed at inducing humoral immune responses however alum is a poor inducer of cellular immune responses. Chitosan is a cationic polysaccharide that has been examined in an adjuvant setting due to its biocompatible and biodegradable nature. The polysaccharide has been shown to have the capacity to induce Th1 cell responses following vaccination by injection or mucosal routes, supporting its application as an alternative to alum for vaccines that promote cell-mediated immunity. The objective of this research was to identify the relationship between the physico-chemical properties of chitin-derived polymers and the type of response induced. Treatment of DCs with a range of chitin-derived polymers with varying degrees of deacetylation revealed that polymers with a higher degree of deacetylation promote greater DC maturation and interferon production, dependent on signalling through the type I IFN receptor and the adaptor protein STING. Furthermore, highly deacetylated polymers were also shown to enhance antigen-specific Th1 responses in a STING-type I IFN-dependent manner. Overall these results indicate that through engagement with the STING-IFNAR pathway, the degree of chitosan deacetylation is a key determinant of the immune enhancing effects, with a higher degree of deacetylation leading to greater immunostimulatory effects. To date, no specific receptors have been identified as mediators of the interaction between chitosan and DCs. However several receptors have been associated with the recognition of chitin, chitosan?s naturally occurring precursor, including the C-type lectin receptor (CLR), Dectin-1. Thus a potential role for Dectin-1 in the recognition of chitosan by DCs was investigated. Previous studies have shown that while chitosan uptake by DCs is not dependent on dectin-1, the induction of type 1 interferons is compromised in the absence of the CLR. Furthermore the upregulation of DC activation markers by chitosan are abrogated in the absence of dectin-1, providing further evidence of a role for dectin-1 signalling in chitosan adjuvanticity. The activation of the cGAS-STING pathway by chitosan is induced by mitochondrial… Advisors/Committee Members: Lavelle, Edward.

Subjects/Keywords: vaccine; adjuvant; chitosan

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

MORAN, H. (2018). The immunmodulatory properties of chitin-derived polymers are dictated by their deacetylation patterns. (Thesis). Trinity College Dublin. Retrieved from http://hdl.handle.net/2262/82147

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

MORAN, HANNAH. “The immunmodulatory properties of chitin-derived polymers are dictated by their deacetylation patterns.” 2018. Thesis, Trinity College Dublin. Accessed June 24, 2019. http://hdl.handle.net/2262/82147.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

MORAN, HANNAH. “The immunmodulatory properties of chitin-derived polymers are dictated by their deacetylation patterns.” 2018. Web. 24 Jun 2019.

Vancouver:

MORAN H. The immunmodulatory properties of chitin-derived polymers are dictated by their deacetylation patterns. [Internet] [Thesis]. Trinity College Dublin; 2018. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/2262/82147.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

MORAN H. The immunmodulatory properties of chitin-derived polymers are dictated by their deacetylation patterns. [Thesis]. Trinity College Dublin; 2018. Available from: http://hdl.handle.net/2262/82147

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

20. Pusic, Kae Myriam. Immunological investigations to re-engineer a Plasmodium falciparum blood-stage human malaria vaccine.

Degree: 2016, University of Hawaii – Manoa

URL: http://hdl.handle.net/10125/101525

►

Ph.D. University of Hawaii at Manoa 2012.

Despite decades of intensive research, malaria remains one of the most prevalent and devastating infectious diseases in the… (more)

▼

Ph.D. University of Hawaii at Manoa 2012.

Despite decades of intensive research, malaria remains one of the most prevalent and devastating infectious diseases in the developing world. There is dire need for an effective malaria vaccine. The Merozoite Surface Protein of P. falciparum, MSP1-42, is one of the leading candidates for a blood-stage malaria vaccine. However, clinical trials of MSP1-42 show no efficacy. Here, we provide in vivo evidence that T cell epitope regions at the N-termjnus of MSP1-42 (MSP1-33) provide functional help in inducing antibodies to the C-terminal protective fragment (MSP1-19). We further demonstrated that these T cell epitopes positively or negatively influenced antibody responses directed towards MSP1-19. Differential recognition of these regions by humans may play a critical role in natural immunity to MSP1-4;, and may also be a critical determinant of vaccine efficacy. This study provides the rational basis to re-engineer more efficacious MSP1-42 vaccines by selective inclusion and exclusion of MSP1-33 specific T cell epitopes. Another major obstacle in the development of a subunit recombinant MSP1-42 malaria vaccine is the availability of safe and effective adjuvants that can potentiate a robust protective immune response. Currently, the adjuvant formulations suitable for clinical testing are very limited. Alternate strategies to enhance vaccine immunogenicity need to be explored and developed. One such strategy is the use of particle-mediated delivery systems such as nanoparticles. Here, we demonstrated the use of inorganic nanoparticles (<15nm) as a potent vaccine delivery platform to enhance the immunogenicity of the recombinant malaria vaccine antigen without additional adjuvants. Results showed that the inorganic nanoparticle delivery platform was as effective in enhancing immunogenicity as the malaria antigen administered with a clinically acceptable adjuvant. Moreover, the malaria vaccine/nanoparticle formulation induced parasite inhibitory antibodies in more than one animal species. Preliminary toxicity studies showed no significant deviations from normal clinical values. We also investigated the effects of nanoparticle uptake by dendritic cell and macrophages and showed that targeting to these antigen presenting cells may be one of the principle modes of action in enhancing vaccine induced immune responses. Our results indicate that the inorganic nanoparticles is a viable vaccine delivery platform for further clinical development.

Subjects/Keywords: malaria; vaccine; adjuvant

11 more images…

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Pusic, K. M. (2016). Immunological investigations to re-engineer a Plasmodium falciparum blood-stage human malaria vaccine. (Thesis). University of Hawaii – Manoa. Retrieved from http://hdl.handle.net/10125/101525

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Pusic, Kae Myriam. “Immunological investigations to re-engineer a Plasmodium falciparum blood-stage human malaria vaccine.” 2016. Thesis, University of Hawaii – Manoa. Accessed June 24, 2019. http://hdl.handle.net/10125/101525.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Pusic, Kae Myriam. “Immunological investigations to re-engineer a Plasmodium falciparum blood-stage human malaria vaccine.” 2016. Web. 24 Jun 2019.

Vancouver:

Pusic KM. Immunological investigations to re-engineer a Plasmodium falciparum blood-stage human malaria vaccine. [Internet] [Thesis]. University of Hawaii – Manoa; 2016. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/10125/101525.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Pusic KM. Immunological investigations to re-engineer a Plasmodium falciparum blood-stage human malaria vaccine. [Thesis]. University of Hawaii – Manoa; 2016. Available from: http://hdl.handle.net/10125/101525

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Oregon State University

21. Sloat, Brian R. Rational vaccine development 1) Design of a Triantigen Nasal Anthrax Vaccine Candidate 2) A Novel Lecithin Based Nanoparticle as a Vaccine Delivery System.

Degree: PhD, Pharmacy, 2010, Oregon State University

URL: http://hdl.handle.net/1957/15311

► Currently, the only anthrax vaccine licensed for human use in the United States is the Anthrax-vaccine-absorbed (AVA or Biothrax®). AVA suffers from several drawbacks, including… (more)

▼ Currently, the only anthrax vaccine licensed for human use in the United States is the Anthrax-vaccine-absorbed (AVA or Biothrax®). AVA suffers from several drawbacks, including a complicated and lengthy dosing schedule that requires six initial injections administered over eighteen months, followed by annual boosters. Therefore, a new generation anthrax vaccine that can be easily administered for rapid mass immunization and induce strong immune responses not only against the anthrax protective antigen protein, but also against the other virulent factors of Bacillus anthracis. To address these needs, a prototypic triantigen nasal anthrax vaccine candidate that contains a truncated PA (rPA63), the anthrax lethal factor (LF), and the capsular poly-γ-D-glutamic acid (γDPGA) as the antigens and a synthetic double-stranded RNA, polyriboinosinic-polyribocytidylic (pI:C) acid as the adjuvant. This study identified the optimal dose of nasal pI:C in mice, as well as showed that pI:C enhanced the proportion of dendritic cells (DCs) in local draining lymph nodes (LNs) and stimulated DC maturation. The γDPGA was shown to be immunogenic when conjugated to a carrier protein and dosed intranasally to mice. Further, the anti-PGA antibodies (Abs) were shown to be functional because they were able to activate complement and kill PGA-producing bacteria. Nasal immunization with LF alone and PA alone induced strong, functional anti-LF and anti-PA Abs. Nasal immunization of mice with the prototypic tri-antigen vaccine candidate induced strong immune responses against all three antigens. The immune responses protected macrophages against an anthrax lethal toxin challenge in vitro and enabled the immunized mice to survive a lethal dose of anthrax lethal toxin challenge in vivo. When used as a nasal vaccine adjuvant, pI:C is generally considered to be safe. However, repeated high doses of pI:C tended to induce some side effects, including fever and abnormal liver functions. Therefore, new adjuvants are constantly being sought. Over the past several decades, an accumulation of research has demonstrated the usefulness of nanoparticles as antigen carriers with adjuvant activity. A novel lecithin-based nanoparticle was engineered from emulsions. Bovine serum albumin (BSA) and PA proteins were covalently conjugated onto the nanoparticles. Mice immunized with BSA conjugated nanoparticles developed strong anti-BSA Ab responses comparable to that induced by BSA adjuvanted with incomplete Freund’s adjuvant and 6.5-fold stronger than that induced by BSA adsorbed onto aluminum hydroxide. Immunization of mice with the PA-conjugated nanoparticles elicited a quick, strong, and durable anti-PA Ab response that afforded protection of the mice against a lethal dose of anthrax lethal toxin challenge. The adjuvanticity of the nanoparticles was likely due to their ability to move antigens into local draining LNs, to enhance the uptake of the antigens by antigen-presenting cells (APCs), and to activate APCs. Most vaccines require… Advisors/Committee Members: Cui, Zhengrong (advisor), Christensen, J. Mark (committee member).

Subjects/Keywords: vaccine; Anthrax – Vaccination

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Sloat, B. R. (2010). Rational vaccine development 1) Design of a Triantigen Nasal Anthrax Vaccine Candidate 2) A Novel Lecithin Based Nanoparticle as a Vaccine Delivery System. (Doctoral Dissertation). Oregon State University. Retrieved from http://hdl.handle.net/1957/15311

Chicago Manual of Style (16^th Edition):

Sloat, Brian R. “Rational vaccine development 1) Design of a Triantigen Nasal Anthrax Vaccine Candidate 2) A Novel Lecithin Based Nanoparticle as a Vaccine Delivery System.” 2010. Doctoral Dissertation, Oregon State University. Accessed June 24, 2019. http://hdl.handle.net/1957/15311.

MLA Handbook (7^th Edition):

Sloat, Brian R. “Rational vaccine development 1) Design of a Triantigen Nasal Anthrax Vaccine Candidate 2) A Novel Lecithin Based Nanoparticle as a Vaccine Delivery System.” 2010. Web. 24 Jun 2019.

Vancouver:

Sloat BR. Rational vaccine development 1) Design of a Triantigen Nasal Anthrax Vaccine Candidate 2) A Novel Lecithin Based Nanoparticle as a Vaccine Delivery System. [Internet] [Doctoral dissertation]. Oregon State University; 2010. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/1957/15311.

Council of Science Editors:

Sloat BR. Rational vaccine development 1) Design of a Triantigen Nasal Anthrax Vaccine Candidate 2) A Novel Lecithin Based Nanoparticle as a Vaccine Delivery System. [Doctoral Dissertation]. Oregon State University; 2010. Available from: http://hdl.handle.net/1957/15311

Victoria University of Wellington

22. Hunn, Martin Kent. Improving immunotherapy for high grade glioma.

Degree: 2015, Victoria University of Wellington

URL: http://hdl.handle.net/10063/4869

► Glioblastoma multiforme (GBM) is a malignant primary brain tumour that is almost always fatal. Conventional treatment modalities are limited by toxicity. T cell-based immunotherapy is… (more)

▼ Glioblastoma multiforme (GBM) is a malignant primary brain tumour that is almost always fatal. Conventional treatment modalities are limited by toxicity. T cell-based immunotherapy is a promising alternative that has the potential to specifically target tumour cells. The author of this thesis was a principal investigator for a recently completed Phase I clinical trial in which patients with recurrent GBM were treated with surgery, dendritic cell-based immunotherapy and chemotherapy. In addition to conducting the trial in collaboration with others, the author used peripheral blood mononuclear cells from trial participants to assess anti-tumour immune responses before and after treatment. A broad correlation was observed between clinical outcome and anti-tumour immunity, with sustained progression-free survival occurring in two patients with baseline responses that persisted or increased after treatment. However, the overall clinical benefit was modest. For progress to be made, there is a need to develop a more potent vaccine. With this in mind, a novel “Glioma-Gal” vaccine was devised and tested in an orthotopic mouse model of glioma, This simple vaccine consisted of irradiated autologous tumour cells pulsed with the glycolipid alpha-galactosylceramide, an immunoadjuvant that induces invariant Natural Killer T cells to licence endogenous dendritic cells. The vaccine was shown to be effective in a therapeutic setting when accompanied by depletion of regulatory T cells. Mechanistically, vaccine efficacy was dependent on CD4 T cells and the mediastinal lymph node was shown to be an important site of T cell priming. It was further shown that components of the immune system necessary for the vaccine to work were present and competent in a cohort of GBM patients. The final chapters explore the idea of enhancing the therapeutic benefit of this vaccine by targeting certain tumour cell subsets or phenotypes. Cancer stem cells (CSC) are proposed to be a subset of tumour cells with a unique capacity for initiating and maintaining tumours. Eliminating these cells may therefore be both necessary and sufficient to achieve cure. Using the same mouse model, a variety of methods were assessed for their ability to isolate or enrich for a CSC subset. Of these, culture in serum-free medium in the presence of certain growth factors was shown to enrich for a more stem cell-like phenotype. However, a vaccine constructed from these stem cell-like cells was not more effective than the standard vaccine. Next, the author tested the hypothesis that a vaccine manipulated to target chemoresistant cells would be more effective than standard vaccine when used in combination with chemotherapy. However, the modified vaccine showed no advantage over standard vaccine in this model. In the course of these experiments, synergy was observed between the vaccine and the chemotherapy agent doxorubicin. The mechanism responsible for this supra-additive effect remains undetermined but is most likely due to an immunomodulatory effect of low dose doxorubicin.… Advisors/Committee Members: Hermans, Ian.

Subjects/Keywords: Glioma; Immunotherapy; Vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Hunn, M. K. (2015). Improving immunotherapy for high grade glioma. (Doctoral Dissertation). Victoria University of Wellington. Retrieved from http://hdl.handle.net/10063/4869

Chicago Manual of Style (16^th Edition):

Hunn, Martin Kent. “Improving immunotherapy for high grade glioma.” 2015. Doctoral Dissertation, Victoria University of Wellington. Accessed June 24, 2019. http://hdl.handle.net/10063/4869.

MLA Handbook (7^th Edition):

Hunn, Martin Kent. “Improving immunotherapy for high grade glioma.” 2015. Web. 24 Jun 2019.

Vancouver:

Hunn MK. Improving immunotherapy for high grade glioma. [Internet] [Doctoral dissertation]. Victoria University of Wellington; 2015. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/10063/4869.

Council of Science Editors:

Hunn MK. Improving immunotherapy for high grade glioma. [Doctoral Dissertation]. Victoria University of Wellington; 2015. Available from: http://hdl.handle.net/10063/4869

Kansas State University

23. Engels, Justin Allen. Bovine salmonellosis and the challenge of developing cross protective vaccines for this disease.

Degree: MSin Biomedical Sciences, Department of Diagnostic Medicine/Pathobiology, 2017, Kansas State University

URL: http://hdl.handle.net/2097/36229

► Salmonella contamination of meat is a leading cause of foodborne illness around the world. Nontyphoidal Salmonella are responsible for an estimated 94 million infections and… (more)

Subjects/Keywords: Salmonella; Bovine; Vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Engels, J. A. (2017). Bovine salmonellosis and the challenge of developing cross protective vaccines for this disease. (Masters Thesis). Kansas State University. Retrieved from http://hdl.handle.net/2097/36229

Chicago Manual of Style (16^th Edition):

Engels, Justin Allen. “Bovine salmonellosis and the challenge of developing cross protective vaccines for this disease.” 2017. Masters Thesis, Kansas State University. Accessed June 24, 2019. http://hdl.handle.net/2097/36229.

MLA Handbook (7^th Edition):

Engels, Justin Allen. “Bovine salmonellosis and the challenge of developing cross protective vaccines for this disease.” 2017. Web. 24 Jun 2019.

Vancouver:

Engels JA. Bovine salmonellosis and the challenge of developing cross protective vaccines for this disease. [Internet] [Masters thesis]. Kansas State University; 2017. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/2097/36229.

Council of Science Editors:

Engels JA. Bovine salmonellosis and the challenge of developing cross protective vaccines for this disease. [Masters Thesis]. Kansas State University; 2017. Available from: http://hdl.handle.net/2097/36229

Georgia Tech

24. Chang, Timothy Z. Protein nanoparticle vaccines.

Degree: PhD, Chemical and Biomolecular Engineering, 2017, Georgia Tech

URL: http://hdl.handle.net/1853/59778

► Highly conserved pathogen proteins are essential for broadly cross-protective vaccines, but tend to be poorly immunogenic. Protein nanoparticle vaccines made from conserved influenza matrix protein… (more)

▼ Highly conserved pathogen proteins are essential for broadly cross-protective vaccines, but tend to be poorly immunogenic. Protein nanoparticle vaccines made from conserved influenza matrix protein 2 (M2e) trigger specific, adaptive immune responses that soluble protein cannot. Without excipients or adjuvants, protein nanoparticles eliminate the possibility of off-target immune responses, and their abiotic nature makes them amenable to cold chain-independent storage and use. The work described herein (1) tests an expanded range of recombinant influenza proteins as viable components of influenza protein nanoparticle vaccines, (2) establishes the immunological basis behind protein nanoparticle adjuvancy in vitro and in vivo, (3) examines long-term, cold-chain-independent storage of protein nanoparticle vaccines, and (4) explores using molecular adjuvants as nanoparticle coatings for enhancing vaccine efficacy. Nanoparticle size and coating were found to be important design criteria for immunogenic protein nanoparticles, and in vivo biodistribution and in vitro dendritic cell processing of nanoparticles yielded insights into mechanisms of protein nanoparticle adjuvancy. Extended room-temperature wet storage of nanoparticles for up to 3 months was shown to yield no loss in immunogenicity, and the molecular adjuvants flagellin and immunoglobulin were shown to enhance various aspects of the immune response in a mouse immunization model. As cold chain-independent storage is an important goal for disseminating new types of vaccines to the developing world, protein nanoparticles have proven to be an attractive and stable platform technology for the co-delivery of antigen and immunostimulatory adjuvant. Furthermore, the ability of immunoglobulin (Ig) to enhance immune responses to protein nanoparticles yields fundamental insights into the innate immunofeedback mechanisms mediated by this protein. In addition to providing a host-derived means of enhancing adjuvancy, Ig-opsonized protein nanoparticles could serve as a tool for further investigations in the broader field of immunoengineering. Advisors/Committee Members: Champion, Julie (advisor), Wang, Baozhong (committee member), Leavey, Jennifer (committee member), Prausnitz, Mark (committee member), Roy, Krishnendu (committee member).

Subjects/Keywords: Nanoparticle; Vaccine; Immunoengineering

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Chang, T. Z. (2017). Protein nanoparticle vaccines. (Doctoral Dissertation). Georgia Tech. Retrieved from http://hdl.handle.net/1853/59778

Chicago Manual of Style (16^th Edition):

Chang, Timothy Z. “Protein nanoparticle vaccines.” 2017. Doctoral Dissertation, Georgia Tech. Accessed June 24, 2019. http://hdl.handle.net/1853/59778.

MLA Handbook (7^th Edition):

Chang, Timothy Z. “Protein nanoparticle vaccines.” 2017. Web. 24 Jun 2019.

Vancouver:

Chang TZ. Protein nanoparticle vaccines. [Internet] [Doctoral dissertation]. Georgia Tech; 2017. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/1853/59778.

Council of Science Editors:

Chang TZ. Protein nanoparticle vaccines. [Doctoral Dissertation]. Georgia Tech; 2017. Available from: http://hdl.handle.net/1853/59778

University of Oxford

25. Bhatnagar, Sunali. Cavitation-enhanced transdermal vaccine delivery by ultrasound.

Degree: PhD, 2014, University of Oxford

URL: https://ora.ox.ac.uk/objects/uuid:069bdaa4-a32f-4c94-9ffa-163e63c85e20 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.711764

► Currently, the most common route for vaccine delivery is by intramuscular injection with a needle and syringe. Injection has number of disadvantages, such as risk… (more)

▼ Currently, the most common route for vaccine delivery is by intramuscular injection with a needle and syringe. Injection has number of disadvantages, such as risk of infection at the i njection site, needle prick injuries, and needle phobia that leads to significant levels of patient non-compliance. Therefore, the focus of this thesis is the development of an alternative ultrasound-assisted transdermal vaccine delivery system. To do so, we target immunological Langerhans cells in the epidermal layer of the skin that efficiently provoke an immune response. The stratum corneum (SC) is a barrier that prevents conventional transdermal vaccine delivery. Methods such as microneedles, iontophoresis and thermal ablation are presented in literature for the permabilisation of this layer. Sonophoresis is the use of ultrasound to transport molecules through a medium. Previous studies have demonstrated that the key underpinning mechanism is inertial cavitation, which leads to permeabilisation of the SC and facilitates transdermal delivery. Most studies to date have pre-exposed the skin to ultrasound prior to delivery of a vaccine in liquid form as a droplet placed on the skin. This approach is not practical for widespread use, but more importantly fails to take advantage of the potential of cavitation-mediated micro streaming to enhance active transport of molecules beyond the permeabilised skin. The focus of the present work is the development of a complete system that enables storage of the vaccine in a readily useable gel form whilst promoting and monitoring cavitation activity to simultaneously permeabilise the skin and enhance transdermal vaccine transport. Through initial in vitro studies, we first demonstrated that inertial cavitation can be exploited to promote the active transport of molecular entities such as vaccine molecules from a gel into a biological medium. A gel vaccine dosage formulation is utilised in order to mimic current clinically approved and established clinical ultrasound coupling gel formulations. By comparing the effects mediated at two ultrasound frequencies (0.256 MHz vs 1 MHz) which preferentially promote cavitational microstreaming or acoustic streaming, ultrasound parameters most conducive to producing high levels of inertial cavitation were identified as 0.256 MHz and peak rarefactional pressures on the order of 1 MPa. Three vaccine loaded gels were then formulated with either micro- or nano-sized cavitation nuclei and assessed for the optimal acoustic and chemical characteristics at the predetermined ultrasound parameters. Nano-sized nuclei were shown to be most effective at lowering the inertial cavitation threshold, as well as instigating the highest and most sustained levels of inertial cavitation as indicated by broadband acoustic emissions at the ultrasound focus, without causing any structural damage to the vaccine molecules themselves. Ex vivo data has shown that nanoscale-nucleated inertial cavitation at the skin surface delivered a model vaccine Ovalbumin (OVA) to depths of 500 μm…

Subjects/Keywords: 614.4; Vaccine delivery

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Bhatnagar, S. (2014). Cavitation-enhanced transdermal vaccine delivery by ultrasound. (Doctoral Dissertation). University of Oxford. Retrieved from https://ora.ox.ac.uk/objects/uuid:069bdaa4-a32f-4c94-9ffa-163e63c85e20 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.711764

Chicago Manual of Style (16^th Edition):

Bhatnagar, Sunali. “Cavitation-enhanced transdermal vaccine delivery by ultrasound.” 2014. Doctoral Dissertation, University of Oxford. Accessed June 24, 2019. https://ora.ox.ac.uk/objects/uuid:069bdaa4-a32f-4c94-9ffa-163e63c85e20 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.711764.

MLA Handbook (7^th Edition):

Bhatnagar, Sunali. “Cavitation-enhanced transdermal vaccine delivery by ultrasound.” 2014. Web. 24 Jun 2019.

Vancouver:

Bhatnagar S. Cavitation-enhanced transdermal vaccine delivery by ultrasound. [Internet] [Doctoral dissertation]. University of Oxford; 2014. [cited 2019 Jun 24]. Available from: https://ora.ox.ac.uk/objects/uuid:069bdaa4-a32f-4c94-9ffa-163e63c85e20 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.711764.

Council of Science Editors:

Bhatnagar S. Cavitation-enhanced transdermal vaccine delivery by ultrasound. [Doctoral Dissertation]. University of Oxford; 2014. Available from: https://ora.ox.ac.uk/objects/uuid:069bdaa4-a32f-4c94-9ffa-163e63c85e20 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.711764

University of Rochester

26. Block, Olivia Kazumi Tono. Evaluation of Dengue Envelope Glycoprotein Domain III as a Subunit Vaccine Candidate for Prophylaxis of Dengue Hemorrhagic Fever/Shock Syndrome.

Degree: PhD, 2011, University of Rochester

URL: http://hdl.handle.net/1802/14602

► Antibody dependent enhancement (ADE) of dengue viral (DENV) infectivity poses a significant challenge to the development of broadly effective vaccines for the prevention of dengue… (more)

▼ Antibody dependent enhancement (ADE) of dengue viral (DENV) infectivity poses a significant challenge to the development of broadly effective vaccines for the prevention of dengue fever (DF), dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). In this phenomenon, antibodies generated during an initial (primary) infection with one of four circulating DENV serotypes cross-react with, but fail to neutralize, a subsequently infecting serotype. The formation of such immune complexes is thought to enhance DENV infectivity by facilitating entry and subsequent replication of the virus in cells of the immune system that bear antibody Fcγ receptors. To address the need to stimulate a balanced neutralizing antibody response against all four DENV serotypes, most current vaccine strategies involve the administration of tetravalent live, attenuated or recombinant viral formulations that typically elicit both serotype-specific neutralizing, and antigenically cross-reactive but non-neutralizing, antibody responses. Thus, in the event that a balanced response is not achieved, all such formulations have the potential to facilitate ADE. In this thesis, I describe a DENV subunit vaccine strategy that involves administration of only one of three domains of the DENV envelope (E) glycoprotein derived from all four DENV serotypes. Domain III (dIII) is attractive for this purpose because it appears to contain epitopes capable of eliciting primarily serotype-specific virus neutralizing antibody responses. Here I examine the potential utility of an E glycoprotein dIII-based strategy to mediate broadly protective (i.e., tetravalent) DENV neutralizing antibody responses with minimal associated ADE activity. In addition, I investigate the mechanism by which DENV-immune complexes enhance entry and viral infectivity in cells expressing Fcγ receptors utilizing a panel of epitope-matched immunoglobulin switch variants and cell lines engineered to express either FcγRI or FcγRII. Results demonstrate that DENV neutralization is modulated by the antibody Fc region in a manner that is dependent upon IgG subclass, likely through effects on virion and FcγR binding. Thus, the IgG antibody subclass profile generated by DENV infection and/or vaccination appears to be a critically important parameter in the development of safe and effective vaccines for the prevention of DF, DHF and DSS.

Subjects/Keywords: Dengue; Vaccine; Envelope

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Block, O. K. T. (2011). Evaluation of Dengue Envelope Glycoprotein Domain III as a Subunit Vaccine Candidate for Prophylaxis of Dengue Hemorrhagic Fever/Shock Syndrome. (Doctoral Dissertation). University of Rochester. Retrieved from http://hdl.handle.net/1802/14602

Chicago Manual of Style (16^th Edition):

Block, Olivia Kazumi Tono. “Evaluation of Dengue Envelope Glycoprotein Domain III as a Subunit Vaccine Candidate for Prophylaxis of Dengue Hemorrhagic Fever/Shock Syndrome.” 2011. Doctoral Dissertation, University of Rochester. Accessed June 24, 2019. http://hdl.handle.net/1802/14602.

MLA Handbook (7^th Edition):

Block, Olivia Kazumi Tono. “Evaluation of Dengue Envelope Glycoprotein Domain III as a Subunit Vaccine Candidate for Prophylaxis of Dengue Hemorrhagic Fever/Shock Syndrome.” 2011. Web. 24 Jun 2019.

Vancouver:

Block OKT. Evaluation of Dengue Envelope Glycoprotein Domain III as a Subunit Vaccine Candidate for Prophylaxis of Dengue Hemorrhagic Fever/Shock Syndrome. [Internet] [Doctoral dissertation]. University of Rochester; 2011. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/1802/14602.

Council of Science Editors:

Block OKT. Evaluation of Dengue Envelope Glycoprotein Domain III as a Subunit Vaccine Candidate for Prophylaxis of Dengue Hemorrhagic Fever/Shock Syndrome. [Doctoral Dissertation]. University of Rochester; 2011. Available from: http://hdl.handle.net/1802/14602

University of New South Wales

27. Sharpe, Sue. Immunoprophylaxis against salmonella in commercial layer chickens.

Degree: Biotechnology & Biomolecular Sciences, 2016, University of New South Wales

URL: http://handle.unsw.edu.au/1959.4/56953 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:42142/SOURCE02?view=true

► Salmonellosis is one of the most common foodborne bacterial diseases globally. Salmonella does not commonly cause disease in poultry; however they are important reservoirs of… (more)

▼ Salmonellosis is one of the most common foodborne bacterial diseases globally. Salmonella does not commonly cause disease in poultry; however they are important reservoirs of Salmonella in the human food chain and management is critical. Attenuated or inactivated Salmonella vaccines have had variable impact upon colonisation. An aroA gene deleted attenuated live vaccine has been released in Australia, whilst an inactivated vaccine has been successfully used by an Australian poultry company for some years.The main aim of this project was to evaluate the efficacy of a Salmonella Typhimurium (ST) attenuated vaccine, alone or in combination with an inactivated multivalent autogenous vaccine that contained Salmonella Typhimurium, Salmonella Infantis, Salmonella Zanzibar and Salmonella Montevideo, administered by four delivery methods, to aid the control of Salmonella in egg layer chickens. Following vaccination, a number of the birds were challenged at four ages with one of the following field-isolated serovars: Typhimurium, Infantis or Virchow. Twenty-one days following challenge the birds were euthanized and their caeca cultured for Salmonella. Throughout the study, the birds were bled at various ages to measure seroconversion, assessed as anti-Salmonella Typhimurium antibody levels; pre and post challenge.The quantitative investigation of the challenge strain in the caecum revealed a statistically significant (p < 0.05) lower challenge strain burden in the parenteral vaccinated groups compared with the non-vaccinated control group up to an age of 22 weeks. The antibody responses varied, though the combination of the attenuated vaccine given by subcutaneous injection at 6 weeks and the inactivated vaccine given by intramuscular injection at 12 weeks of age gave the highest titres. The protective effects were demonstrated for the homologous challenge strains but not the heterologous strain. This study has shown that it is necessary to provoke a strong humoral response by vaccination, in commercial layers to reduce the contamination of eggs and egg products. The pre-lay period of layers is considered an especially important age to have control over Salmonella colonisation. Thereby, if the bird is protected, the transmission of Salmonella serovars of public health importance will be reduced, if not eliminated. Advisors/Committee Members: Cox, Julian, Faculty of Engineering, UNSW, Groves, Peter, The University of Sydney.

Subjects/Keywords: Vaccine; Salmonella; Poultry

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Sharpe, S. (2016). Immunoprophylaxis against salmonella in commercial layer chickens. (Masters Thesis). University of New South Wales. Retrieved from http://handle.unsw.edu.au/1959.4/56953 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:42142/SOURCE02?view=true

Chicago Manual of Style (16^th Edition):

Sharpe, Sue. “Immunoprophylaxis against salmonella in commercial layer chickens.” 2016. Masters Thesis, University of New South Wales. Accessed June 24, 2019. http://handle.unsw.edu.au/1959.4/56953 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:42142/SOURCE02?view=true.

MLA Handbook (7^th Edition):

Sharpe, Sue. “Immunoprophylaxis against salmonella in commercial layer chickens.” 2016. Web. 24 Jun 2019.

Vancouver:

Sharpe S. Immunoprophylaxis against salmonella in commercial layer chickens. [Internet] [Masters thesis]. University of New South Wales; 2016. [cited 2019 Jun 24]. Available from: http://handle.unsw.edu.au/1959.4/56953 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:42142/SOURCE02?view=true.

Council of Science Editors:

Sharpe S. Immunoprophylaxis against salmonella in commercial layer chickens. [Masters Thesis]. University of New South Wales; 2016. Available from: http://handle.unsw.edu.au/1959.4/56953 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:42142/SOURCE02?view=true

University of Ottawa

28. Muralidharan, Abenaya. Towards Better Understanding of Respiratory Syncytial Virus (RSV) Vaccine-Induced Enhanced Disease .

Degree: 2019, University of Ottawa

URL: http://hdl.handle.net/10393/39216

At the author’s request, the abstract has been removed due to the confidential nature of the thesis. It will be added once the embargo period has passed.

Subjects/Keywords: Vaccine; RSV; Immunopathology

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Muralidharan, A. (2019). Towards Better Understanding of Respiratory Syncytial Virus (RSV) Vaccine-Induced Enhanced Disease . (Thesis). University of Ottawa. Retrieved from http://hdl.handle.net/10393/39216

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Muralidharan, Abenaya. “Towards Better Understanding of Respiratory Syncytial Virus (RSV) Vaccine-Induced Enhanced Disease .” 2019. Thesis, University of Ottawa. Accessed June 24, 2019. http://hdl.handle.net/10393/39216.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Muralidharan, Abenaya. “Towards Better Understanding of Respiratory Syncytial Virus (RSV) Vaccine-Induced Enhanced Disease .” 2019. Web. 24 Jun 2019.

Vancouver:

Muralidharan A. Towards Better Understanding of Respiratory Syncytial Virus (RSV) Vaccine-Induced Enhanced Disease . [Internet] [Thesis]. University of Ottawa; 2019. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/10393/39216.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Muralidharan A. Towards Better Understanding of Respiratory Syncytial Virus (RSV) Vaccine-Induced Enhanced Disease . [Thesis]. University of Ottawa; 2019. Available from: http://hdl.handle.net/10393/39216

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

29. Jaiswal Varun. Development of Immunoinformatics Tools for Vaccine Design;.

Degree: 2014, Jaypee University of Information Technology, Solan

URL: http://shodhganga.inflibnet.ac.in/handle/10603/26246

►

Though vaccines against many diseases are available but those are not effective when strain variability is very high and immune response is poor These strain… (more)

Subjects/Keywords: Adhesin; Epitope-based Vaccine Candidate; Host Pathogen Interaction; Jenner; Universal Influenza Vaccine (UIV); Vaccine Design

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Varun, J. (2014). Development of Immunoinformatics Tools for Vaccine Design;. (Thesis). Jaypee University of Information Technology, Solan. Retrieved from http://shodhganga.inflibnet.ac.in/handle/10603/26246

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Varun, Jaiswal. “Development of Immunoinformatics Tools for Vaccine Design;.” 2014. Thesis, Jaypee University of Information Technology, Solan. Accessed June 24, 2019. http://shodhganga.inflibnet.ac.in/handle/10603/26246.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Varun, Jaiswal. “Development of Immunoinformatics Tools for Vaccine Design;.” 2014. Web. 24 Jun 2019.

Vancouver:

Varun J. Development of Immunoinformatics Tools for Vaccine Design;. [Internet] [Thesis]. Jaypee University of Information Technology, Solan; 2014. [cited 2019 Jun 24]. Available from: http://shodhganga.inflibnet.ac.in/handle/10603/26246.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Varun J. Development of Immunoinformatics Tools for Vaccine Design;. [Thesis]. Jaypee University of Information Technology, Solan; 2014. Available from: http://shodhganga.inflibnet.ac.in/handle/10603/26246

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Boston University

30. Johnson, Meredith. Motivational interviewing for vaccine hesitant parents.

Degree: MS, Physician Assistant Program, 2017, Boston University

URL: http://hdl.handle.net/2144/26708

► BACKGROUND: The widespread use of vaccines led to significant decline in multiple potentially fatal infectious diseases. Recently, there has been an increase in vaccine hesitancy.… (more)

▼ BACKGROUND: The widespread use of vaccines led to significant decline in multiple potentially fatal infectious diseases. Recently, there has been an increase in vaccine hesitancy. Measles and pertussis outbreaks throughout the United States have put a spotlight on this urgent healthcare issue. Motivational interviewing is a counseling tactic that is gaining popularity and is being studied for its efficacy in preventative medicine and psychological disorders. It aims to inspire people to make behavioral changes through collaborative relationships with their provider by understanding how current actions do not translate into their health goals. LITERATURE REVIEW FINDINGS: Vaccine hesitancy is growing. Communities with decreased immunization rates are associated with a higher risk of disease outbreak. Increasing rates of undervaccinated children are likely due to increases in non-medical exemptions. Many parents, regardless of their vaccine hesitancy status, are concerned about vaccine safety. Vaccine hesitant parents refuse vaccines due to philosophical and religious beliefs, conspiracy theories, and safety concerns. Parents feel that providers do not adequately address their concern. Providers report not having the training to discredit parental concerns. The majority of parents describe their child’s pediatrician as their most trusted source of vaccine information. Parents who receive vaccine information from a provider are more likely to comply with the recommended childhood vaccine schedule. The most efficient way to discuss vaccines with parents has yet to be determined. PROPOSED PROJECT: This is a proposed QI research project for the Pediatric Clinic at Boston Medical Center. Providers would be trained in motivational interviewing during several sessions that included lectures and small group practice sessions with systematic feedback. During the intervention, parents who refuse vaccines for their child, aged 0-6 years old, will receive motivational interviewing from the provider. The proportion of the vaccine hesitant parents who accept the offered vaccine after will be analyzed. The pre and post intervention vaccination rates for the entire clinic will also be assessed. Data collection will be preformed through retrospective chart review. The project aims to increase provider confidence on vaccine counseling, educate providers on reasons for hesitancy, and improve compliance with the CDC recommended vaccine schedule. CONCLUSION: While most Americans continue to vaccinate their children according to the CDC’s recommended schedule, constant vigilance is required to maintain high immunization rates to protect our communities. Motivational interviewing is goal-oriented to alter a specific behavior and would allow providers to engage in an open, persuasive dialogue about parental vaccine concerns.

Subjects/Keywords: Medicine; Anti-vaccine; Childhood vaccines; Immunization schedule; Motivational interviewing; Vaccine hesitancy; Vaccine hesitant parents

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Johnson, M. (2017). Motivational interviewing for vaccine hesitant parents. (Masters Thesis). Boston University. Retrieved from http://hdl.handle.net/2144/26708

Chicago Manual of Style (16^th Edition):

Johnson, Meredith. “Motivational interviewing for vaccine hesitant parents.” 2017. Masters Thesis, Boston University. Accessed June 24, 2019. http://hdl.handle.net/2144/26708.

MLA Handbook (7^th Edition):

Johnson, Meredith. “Motivational interviewing for vaccine hesitant parents.” 2017. Web. 24 Jun 2019.

Vancouver:

Johnson M. Motivational interviewing for vaccine hesitant parents. [Internet] [Masters thesis]. Boston University; 2017. [cited 2019 Jun 24]. Available from: http://hdl.handle.net/2144/26708.

Council of Science Editors:

Johnson M. Motivational interviewing for vaccine hesitant parents. [Masters Thesis]. Boston University; 2017. Available from: http://hdl.handle.net/2144/26708

		in
And / Or
		in
And / Or
		in
And / Or
		in

Open Access Theses and Dissertations